Reported 2 days ago
Johnson & Johnson (JNJ) stands out among the Dogs of the Dow for its defensive strength and robust financial performance. With a reported revenue of $23.7 billion in Q2 2025, representing a 5.77% growth year-over-year, JNJ has also raised its annual sales outlook and adjusted its earnings per share forecast upward. The company is well-positioned for future growth with significant upcoming approvals in critical healthcare areas and a longstanding record of increasing dividends for 63 years. Currently, JNJ offers a dividend yield of 3.09%, making it an attractive option for investors.
Source: YAHOO